The relationship between long-term glycaemic control and the activity of coagulation inhibitors was investigated in 60 non-insulin-dependent diabetes mellitus (NIDDM) patients not on insulin therapy. Overall, the activities of antithrombin III (AT III) (median 96%, range 65–133%), protein C (127%, 24–190%) and protein S (130%, 54–163%) were not reduced. Patients in poor long-term glycaemic control as verified by increased glycated haemoglobin (HbA1c) demonstrated significantly decreased median AT III activity in comparison with patients in good glycaemic control (92% vs 101%,P=0.016). However, individual values for AT III activity were not below the critical limit of 60%. An inverse correlation between AT III activity and long-term glycaemic control (HbA1c) was calculated (r=−0.378,P=0.0029). As AT III concentrations were found to be normal, we propose that non-enzymatic glycation leads to reduced activity of AT III without affecting its concentration.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Colwell JA. Vascular thrombosis in type II diabetes mellitus.Diabetes 1993:42; 8–11.
Donahue RP, Orhchard TJ. Diabetes mellitus and macrovascular complications. An epidemiological perspective.Diabetes Care 1992:15; 1141–55.
Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s.Nature 1993:362; 801–9.
Nachman RL, Silverstein R. Hypercoagulable states.Ann Intern Med 1993:119; 819–27.
Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects.Diabetologia 1993:36; 1119–25.
Hatton MWC, Richardson M, Winocour PD. On glucose transport and non-enzymic glycation of proteins in vivo.J Theor Biol 1993:161; 481–90.
Ostermann H, Van de Loo J. Factors of the hemostatic system in diabetic patients. A survey of controlled studies.Haemostasis 1986:16; 386–416.
Christie M, Fritschi J, Lämmle B, et al. Fifteen coagulation and fibrinolysis parameters in diabetes mellitus and in patients with vasculopathy.Thromb Haemost 1984:52: 138–43.
Grignani G, Gamba G, Geroldi D, et al. Enhanced antithrombotic mechanisms in pateints with maturity-onset diabetes mellitus without thromboembolic complications.Thromb Haemost 1981:46; 648–51.
Donders SHJ, Lustermans FAT, Van Wersch JWJ. Glycometaboic control, lipids, and coagulation parameters in patients with non-insulin-dependent diabetes mellitus.Int J Clin Lab Res 1993:23; 155–9.
Ceriello A, Dello Rosso P, Zuccotti C, et al. Decreased antithrombin III activity in diabetes may be due to non-enzymatic glycosylation. A preliminary report.Thromb Haemost 1983:50; 633–4.
Hall P, Tryon E, Nikolai TF, Roberts RC. Functional activities and nonenzymatic glycosylation of plasma proteinase inhibitors in diabetes.Clin Chim Acta 1986:160; 55–62.
Schwarz HP, Schernthaler G, Griffin JH.Decreased plasma levels of protein S in well-controlled type I diabetes mellitus.Thromb Haemost 1987:57; 240.
Biondi G, Sorano GG, Conti M, et al. The behaviour of protein C in diabetes is still an open question.Thromb Haemost 1991:66; 267.
Knöbl P, Schernthaler G, Schnack C, et al. Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients.Diabetologia 1993:36; 1045–50.
Steiner M, Reinhardt K, Burstein C, et al. Coagulation inhibitors and soluble thrombomodulin in patients suffering from non-insulin dependent diabetes mellitus (NIDDM) (abstract).Thromb Haemost 1993:69; 1215.
WHO Study Group.Diabetes mellitus. Technical report series 727. Geneva: WHO, 1985; 1–113.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.New Engl J Med 1993:329; 977–86.
VanBoeckel MAM. The role of glycation in aging and diabetes.Mol Biol Rep 1991:15; 57–64.
Ceriello A, Giugliano D, Dello Russo P, et al. Metabolic control may alter antithrombin III activity but not its plasma concentration in diabetes: a possible role for nonenzymatic glycosylation.Diabetes Care 1986:9, 32–5.
Ceriello A, Giugliano D, Quatraro A, et al. Induced hyperglycemia alters antithrombin III activity but not its plasma concentration in healthy normal plasma.Diabetes 1987:36; 320–3.
Hedin U, Frebelius S, Sanchez J, Dryjski M, Swedenborg J. Antithrombin III inhibits thrombininduced proliferation in human arterial smooth muscle cells.Arterioscler Thromb 1994:14; 254–60.
Grignani G, Gamba G, Geroldi D, et al. Enhanced antithrombotic mechanisms in patients with maturity-onset diabetes mellitus without thromboembolic complications.Thromb Haemost 1981:46; 648–51.
Ceriello A, Quatraro A, Dello Rosso P, et al. Protein C deficiency in insulin-dependent diabetes: a hyperglycemia-related phenomenon.Thromb Haemost 1990:64; 104–7.
Ceriello A, Giugliano D, Quatraro A, et al. Possible role for increased C4b-binding protein level in acquired protein S deficiency in type I diabetes.Diabetes 1990:39; 447–9.
About this article
Cite this article
Reinhardt, K.M., Burstein, C., Nagel, H. et al. Coagulation inhibitors and glycaemic control in non-insulin-dependent diabetes mellitus. Glycosylation & Disease 1, 287–291 (1994). https://doi.org/10.1007/BF00919337
- antithrombin III
- glycaemic control
- non-insulin-dependent diabetes mellitus
- protein C
- protein S